Article
Fixed-combination drug yields superior IOP lowering
New Orleans—Results of a prospective, randomized, double-masked study demonstrate a fixed combination of travoprost 0.004% and timolol 0.5% (Extravan, Alcon Laboratories) administered once daily is safe, well-tolerated, and offers better IOP lowering than monotherapy using either of its components, said Howard S. Barnebey, MD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
